Zymes Bioscience

Delhi, India Founded: 2012 • Age: 14 yrs
Develops innovative antibiotic therapies for medical treatment and bacterial resistance.
Annual revenue $3.6M Latest available
Total funding - Funding intelligence
Employees 51 Tracked headcount
Investors - Known backers
Products 2 Services tracked
Competitors - Brand Intelligence

About Zymes Bioscience

Zymes Bioscience is a company based in Delhi (India) founded in 2012 by Ashok Kumar Papneja, Mohit Bhatia, and Chandan Chopra. It operates as a B2B. The company has 51 employees as of March 31, 2022. Zymes Bioscience offers products and services including Antibiotic Therapies and Innovative Products Pipeline.

  • Headquarter Delhi, India
  • Employees 51 as on 31 Mar, 2022
  • Founders Ashok Kumar Papneja, Mohit Bhatia, Chandan Chopra
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Legal Name Zymes Bioscience Private Limited
  • Date of Incorporation 09 Apr, 2012
  • Jurisdiction New Delhi, Delhi, India
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $3.63 M (USD)
    126.94
    as on Mar 31, 2022
  • Net Profit
    $174.09 K (USD)
    27.82
    as on Mar 31, 2022
  • EBITDA
    $100.26 K (USD)
    135.17
    as on Mar 31, 2022
  • Latest Funding Round
    Not available
  • Investors
    Not available
  • Employee Count
    51

    as on Mar 31, 2022

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Zymes Bioscience

Zymes Bioscience offers a comprehensive portfolio of products and services, including Antibiotic Therapies and Innovative Products Pipeline.

Product name locked
Category locked
Primary

Therapies designed to treat acute illnesses and combat bacterial resistance effectively.

Product name locked
Category locked
Locked

Upcoming solutions for overcoming bacterial resistance in medical applications.

Funding Insights of Zymes Bioscience

Premium access

Detailed funding history for Zymes Bioscience

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Zymes Bioscience

Investments
Premium access

Investment portfolio details for Zymes Bioscience

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Zymes Bioscience

Premium access

Detailed financials for Zymes Bioscience

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Zymes Bioscience Comparisons

Zymes Bioscience Primary company
Description
Develops innovative antibiotic therapies for medical treatme...
Location
Delhi, India
Founded Year
2012
Annual Revenue
$3.63 M (USD)
Net Profit
$174.09 K (USD)
EBITDA
$100.26 K (USD)
Employees
51
As of 2022
Premium access

Peer comparison for Zymes Bioscience

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Zymes Bioscience

Premium access

Detailed competitors of Zymes Bioscience

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Zymes Bioscience

Premium access

Complete news archive for Zymes Bioscience

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Zymes Bioscience

Zymes Bioscience was founded in 2012.

Zymes Bioscience is headquartered in Delhi, India. It is registered at Delhi, Delhi, India.

As of Mar 31, 2022, the latest employee count at Zymes Bioscience is 51.

Annual revenue of Zymes Bioscience is $3.63M as on Mar 31, 2022.

Zymes Bioscience focuses on creating innovative therapies for acute and life-threatening conditions, particularly in antibiotic treatment to address bacterial resistance. The company supports the medical community through product development and pipeline innovations. Based in New Delhi, it emphasizes team growth, customer input, and reliable solutions. They aim to deliver effective medical treatments while fostering collaboration and career opportunities within a dedicated team.

Zymes Bioscience offers Antibiotic Therapies and Innovative Products Pipeline.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available